XPOVIO(R) (sélinexor) est maintenant financé au Québec
Oakville, Ontario--(Newsfile Corp. - 18 novembre 2025) - FORUS Therapeutics a le plaisir d'annoncer que XPOVIO® (sélinexor) bénéficie d'un financement public au Québec pour le traitement du myélome multiple depuis le 6 novembre 2025. Veuillez consulter le lien suivant pour connaître tous les critères de financement : Liste des médicaments fournis en établissement | Régie de l'assurance maladie du Québec (RAMQ) (http
Healthcare and Hospitals, Pharmaceuticals
2025-11-18 9:00 AM EST | FORUS Therapeutics Inc.
Envoy Medical Achieves Six-Month Milestone with First 10 Patients in Acclaim(R) Cochlear Implant Clinical Trial
White Bear Lake, Minnesota--(Newsfile Corp. - November 18, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that all 10 patients in the first stage of its pivotal clinical trial for the investigational Acclaim® fully implanted cochlear implant have successfully completed their six-month follow-up visits. Notably, there have been no serious adverse events reported, rei
Biotechnology, Healthcare and Hospitals
2025-11-18 8:00 AM EST | Envoy Medical, Inc.
FendX and Aquaox Sign MOU to Pursue Innovation in Sustainable Pathogen Elimination
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to announce it has signed a Memorandum of Understanding ("MOU") dated November 17, 2025 with Aquaox LLC ("Aquaox"), a U.S. based manufactu
Technology, Healthcare and Hospitals, Health
2025-11-18 6:30 AM EST | FendX Technologies Inc.
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress
King of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation highlighting INTASYL® siRNA Drug Technology will be held at the Advanced Therapies USA 2025 Congress in Philadelphia, PA at the Pennsylvania Convention
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-17 8:45 AM EST | Phio Pharmaceuticals Corp.
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Ontario and Chicago, Illinois--(Newsfile Corp. - November 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into a new senior secured credit agreement with National Bank of Canada as administrative agent. The credit agreement provides for a US$21.0 million term loan facility and a US$5.0 million revolving loan facility. The term loan facility benefits from an additional US$10.0 million delayed draw feature, intended to finance future licensing and acquisitio
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-17 8:30 AM EST | Medexus Pharmaceuticals Inc.
ADIA Nutrition Inc. Requests SIC Code Update to 2836 (Biological Products) with SEC and OTC Markets
Winter Park, Florida--(Newsfile Corp. - November 17, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, today announced it has filed with the SEC to update its Standard Industrial Classification (SIC) code from 2834 (Pharmaceutical Preparations) to 2836 (Biological Products, Except Diagnostic) and with OTC Markets to update from 6719 (Holding Companies, N.E.C.) to 2836 (Biological Products, Except Diagnostic), accurately reflecting its core business of manufacturin
Healthcare and Hospitals, Health
2025-11-17 8:00 AM EST | Adia Nutrition Inc.
Adaptimmune Announces Changes to Board and Executive Leadership Team
Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes to the Company's Board of Directors ("Board") and its Executive Leadership team, which are effective from November 14, 2025. Christopher (Chris) Hill, currently Chief Financial Officer ("CFO") of the Company, has been appointed as Chief Executive Officer ("CEO") and a Director of the Company,
Biotechnology, Healthcare and Hospitals
2025-11-17 7:30 AM EST | Adaptimmune Therapeutics PLC
Theralase(R) Investor Conference Call Reminder
Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses reminds investors that it will host a conference call on Wednesday, November 19th at 11:00 am ET to provide an update on the Company's ongoing Phase II clinical stu
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-11-17 7:00 AM EST | Theralase Technologies Inc.
Scryb Highlights New U.S. Institutional Fund Investment in Cybeats; Strengthens Long-Term Outlook
Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company"), is pleased to highlight the closing of an investment by U.S.-based IFCM MicroCap Fund LP, managed by Intelligent Fanatics Capital Management, into Cybeats Technologies Corp. ("Cybeats"). The investment fund was the sole participant in this $1.44 million private placement.1 Scryb maintains its position as the largest institutional shareholder of Cybeats
Biotechnology, Healthcare and Hospitals, Health
2025-11-17 7:00 AM EST | Scryb Inc.
Governance Professionals of Canada Announce the 2025 Winners for the Excellence in Governance Awards
Toronto, Ontario--(Newsfile Corp. - November 15, 2025) - Governance Professionals of Canada (GPC) announced the winners of the 2025 Excellence in Governance Awards (EGAs)/Prix d'excellence en gouvernance, at its 12th annual awards ceremony on November 13th at the Carlu in Toronto. This prestigious annual gala brings together the governance community to celebrate exemplary governance practices across various sectors and industries in Canada. The EGAs recognize the t
Banking / Financial Services, Education, Healthcare and Hospitals, Oil & Gas
2025-11-15 3:41 PM EST | Governance Professionals of Canada
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the second quarter of fiscal year 2026 ended September 30, 2025 ("Second Quarter"). Consolidated revenues for the three-month period ending September 30, 2025, were $36.3 million, an increase of $17.4 million or approximately 92% as compared to the comparable period
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-14 4:19 PM EST | Elite Pharmaceuticals, Inc.
Winlevi(R) Receives Regulatory Approval in Brazil - Expanding Global Access to a Breakthrough Acne Treatment
Dublin, Ireland--(Newsfile Corp. - November 14, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and dermatology innovations, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved Winlevi® (clascoterone) cream 1% for the treatment of acne vulgaris in patients aged twelve years and older. This milestone marks another key step in Cosmo’s mission to build health confidence worldwide, expanding access to
Healthcare and Hospitals, Health
2025-11-14 1:10 AM EST | Cosmo Pharmaceuticals N.V.
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive Pathology Results at Maximum Dose: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater than 50% (Partial Response) in Third Patient Safety Monitoring Committee Issues Favorable Review of Safety Data at Maximum Dose of INTASYL PH-762 Warrant Inducement Fi
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-13 4:15 PM EST | Phio Pharmaceuticals Corp.
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Ontario and Chicago, Illinois--(Newsfile Corp. - November 12, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's second fiscal quarter ended September 30, 2025 (the company's fiscal Q2 2026). All dollar amounts in this press release are in United States dollars unless specified otherwise. Key business update Medexus is currently focused on delivering strong p
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-12 6:06 PM EST | Medexus Pharmaceuticals Inc.
Adia Med Files Provisional Patent for Breakthrough Regenerative Medical Protocol
Winter Park, Florida--(Newsfile Corp. - November 12, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced regenerative health solutions, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO) for a novel medical protocol designed to enhance regenerative outcomes. This Patent Pending innovation represents a significant advancement in ADIA's mission to deliver cutting-edge, science-backed therapies. The proprie
Healthcare and Hospitals, Health
2025-11-12 9:15 AM EST | Adia Nutrition Inc.
BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to support the Canadian Cancer Society's national plan to reduce lung cancer mortality in Canada by 30% over the next decade. The early detection activities and goals outlined in the 2026-2035 Pan-Canadia
Technology, Biotechnology, Healthcare and Hospitals
2025-11-12 8:30 AM EST | BioMark Diagnostics, Inc.
Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL(R)
Northvale, New Jersey--(Newsfile Corp. - November 12, 2025) - Elite Pharmaceuticals, Inc. (OTCBB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropi
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-12 7:00 AM EST | Elite Pharmaceuticals, Inc.
Area Agencies on Aging Association of Michigan Launches State's First-Ever One-Stop Website Resource for Family Caregivers
Detroit, Michigan--(Newsfile Corp. - November 11, 2025) - The Area Agencies on Aging Association of Michigan (4AMI) has launched Mi Caregiver Connection, a one-stop web resource for caregivers throughout Michigan to connect to one of the local 16 Area Agencies on Aging (AAA) across the state. "We are very excited about this historic launch — it's the first time caregivers across Michigan can access the full statewide network of Area Agencies on Aging through a single, centralized
2025-11-11 11:49 AM EST | Area Agencies on Aging Association of Michigan/Güd Marketing
Cosmo's ESG Rating Upgraded by S&P Global; Strengthens Supplier Sustainability Oversight Engagement, and Italian Manufacturing Plant Awarded EcoVadis Bronze Medal
Dublin, Ireland--(Newsfile Corp. - November 11, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced two major milestones in its sustainability journey, underscoring its commitment to transparency, responsible operations, and ESG leadership. Cosmo’s 2025 S&P Global Corporate Sustainability Assessment has been upgraded to the 67th percentile, a significant improvement from la
Healthcare and Hospitals, Health
2025-11-11 1:01 AM EST | Cosmo Pharmaceuticals N.V.
CardioComm Receives TSX Venture Exchange Approval for Announced Loan Facility
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to announce that it has received approval from the TSX Venture Exchange for its November 3, 2025 announced loan agreement dated November 3, 2025 (the "Loan Agreement") representing aggregate funding of $512,000. The
Technology, Healthcare and Hospitals, Health
2025-11-10 11:37 PM EST | CardioComm Solutions, Inc.